BJP Try Psychiatric Bulletin Online
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
QUICK SEARCH:   [advanced]


     

The British Journal of Psychiatry (2007) 190: 447-448. doi: 10.1192/bjp.bp.105.016535
© 2007 The Royal College of Psychiatrists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in BJP
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Haessler, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haessler, F.

SHORT REPORTS

Zuclopenthixol in adults with intellectual disabilities and aggressive behaviours

Discontinuation study

Frank Haessler, MD

Department of Child and Adolescent Psychiatry, University of Rostock, Rostock

Thomas Glaser, PhD, Manfred Beneke, PhD and Akos F. Pap, MSc

Bayer Vital GmbH, Leverkusen

Ralf Bodenschatz, MD

Private Practice, Mittweida

Olaf Reis, PhD

University of Rostock, Rostock, Germany

on behalf of the Zuclopenthixol Disruptive Behaviour Study Group

Correspondence: Professor Dr Frank Haessler, Department of Child and Adolescent Psychiatry, University of Rostock, Gehlsheimer Strasse 20,18147 Rostock, Germany. Email: frank.haessler{at}med.uni-rostock.de

Declaration of interest T.G., M.B. and A.F.P. are employees of Bayer Vital GmbH.

We investigated the effects of zuclopenthixol on aggressive behaviour in patients with intellectual disabilities by randomly withdrawing it after a 6-week period of open treatment. Of the 49 patients responding to the treatment, 39 took part in a randomised withdrawal trial. The placebo subgroup (n=20) showed more aggressive behaviour as indicated by outcomes observed by external raters on the Modified Overt Aggression Scale than did the continuing subgroup (n=19). The results indicate that discontinuation of zuclopenthixolin this population leads to an increase in aggressive behaviour.


Related articles in BJP:

Highlights of this issue
Sukhwinder S. Shergill
BJP 2007 190: A17. [Full Text]  





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
Copyright © 2007 The Royal College of Psychiatrists.